• FutureMedicine

    Driven by nucleoside R&D to challenge the unmet needs

  • First in Class

    New treatments with unique mechanism of action for patients

  • FOCUS™

    Drug discoveries based on Nucleoside Library Platform

/

Core technology Nucleoside

The core competitiveness of Future Medicine is that it has its own Nuleoside Library platform.

Nucleoside

Lorem ipsum dolor sit amet, consectetur

Platform-FOCUS™

Lorem ipsum dolor sit amet, consectetur

Pipeline

Pipeline Indication Discovery Lead
Optimization
Pre-clinical Phase1 Phase2 Phase3 NDA
FM101 Nonalcoholic Steatohepatitis(NASH)
FM801 비만치료제
FM101 Glaucoma
Diabetic Nephropathy
Primary biliary cholangitis(PBC)
FM301 Refractory Pancreatic Cancer
FM401 Solid Tumors
FM701 Non Small Cell Lung Cancer(NSCLC)
FM203 Viral Infections (COVID19, MERS, Zika)
FM503 Autoimmune Disease
Pipeline Indication Graph
FM101 Nonalcoholic Steatohepatitis(NASH)

Phase2

FM801 비만치료제

Pre-Clinical

FM101 Glaucoma

Phase2

Diabetic Nephropathy

Phase1

Primary biliary cholangitis(PBC)

Phase1

FM301 Refractory Pancreatic Cancer

Pre-Clinical

FM401 Solid Tumors

Pre-Clinical

FM701 Non Small Cell Lung Cancer(NSCLC)

Pre-Clinical

FM203 Viral Infections
(COVID19, MERS, Zika)

Pre-Clinical

FM503 Autoimmune Disease

Pre-Clinical

Pipeline Indication Graph
FM101 Nonalcoholic Steatohepatitis(NASH)

Phase2

FM801 비만치료제

Pre-Clinical

FM101 Glaucoma

Phase2

Diabetic Nephropathy

Phase1

Primary biliary cholangitis(PBC)

Phase1

FM301 Refractory Pancreatic Cancer

Pre-Clinical

FM401 Solid Tumors

Pre-Clinical

FM701 Non Small Cell Lung Cancer(NSCLC)

Pre-Clinical

FM203 Viral Infections
(COVID19, MERS, Zika)

Pre-Clinical

FM503 Autoimmune Disease

Pre-Clinical

Press Release

No posts have been submitted.